FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Teva Pharmaceuticals Valsartan and Hydrochlorothiazide Recall

Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 160 mg/12

Teva Pharmaceuticals USA · North Wales, PA

Risk level
Class II
Reported by FDA
Aug 1, 2018
Recall ID
D-0982-2018
Check your lot numberHow we source this data

Summary

Teva Pharmaceuticals recalled Valsartan and Hydrochlorothiazide starting Jul 16, 2018. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0982-2018 on Aug 1, 2018. Reason: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. Status: Ongoing.

Why it was recalled

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Product description

Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 160 mg/12.5 mg tablets, USP 90-count bottle, Rx Only, Rx Only, Manufactured by: Arrow Pharma (Malta) Ltd. India, Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054. NDC 0591-2316-19.

Lot numbers, UPCs & expiration codes

Lot Numbers: 1191160M, 1191161M, 1191162A, 1219363M, 1219364M, 1219365A, 1225613A, 1233944M, 1233945M, 1253253M, 1253254M

Where it was sold

Product was distributed throughout the United States, including Hawaii and Puerto Rico

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0982-2018
Classification
Class II
Status
Ongoing
Recall initiated
Jul 16, 2018
FDA report date
Aug 1, 2018
Quantity
195,234 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Teva Pharmaceuticals USA

Original FDA data

Every field from FDA enforcement report D-0982-2018, exactly as published.

Show all FDA fields
City
North Wales
State
PA
Status
Ongoing
Country
United States
Event ID
80538
Address
1090 Horsham Rd
Code information
Lot Numbers: 1191160M, 1191161M, 1191162A, 1219363M, 1219364M, 1219365A, 1225613A, 1233944M, 1233945M, 1253253M, 1253254M
Postal code
19454-1505
Report date
Aug 1, 2018
Product type
Drugs
Recall number
D-0982-2018
Classification
Class II
Recalling firm
Teva Pharmaceuticals USA
Product quantity
195,234 bottles
Reason for recall
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 160 mg/12.5 mg tablets, USP 90-count bottle, Rx Only, Rx Only, Manufactured by: Arrow Pharma (Malta) Ltd. India, Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054. NDC 0591-2316-19.
Distribution pattern
Product was distributed throughout the United States, including Hawaii and Puerto Rico
Recall initiation date
Jul 16, 2018
Initial firm notification
Press Release
Center classification date
Jul 24, 2018

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0982-2018, published Aug 1, 2018. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls